Friday, January 21st, 2022 @ 8:30PM

RTSL seems well-positioned for an upward share price movement

Company Summary

RTSL is a growth-oriented aerosol manufacturing company focused on delivery of non-psychoactive cannabinoid compounds.

The Company has developed a new method of formulating and manufacturing pressurized metered dose inhalers (pMDI) that contain and properly aerosolize proprietary formula of one or more patent pending pharmaceutical grade cannabinoid compounds.

Key Metrics @ 1/10/2022

Closing Price	$0.28
52 Week Range	$0.14 to $0.80
Shares Outstanding	193.57M
Shares in the Float	30.86M
% Held by Insiders	67.47%
Shares Authorized	650M
Average Daily Volume: 10 Day	9,600
Market Cap	$54.22M
Reporting Status	SEC Reporting
Financials	Audited
Most Recent Filing: 10-Q  for 09/30/21	Filed:  11/10/2021
Fiscal Year-end	012/31

(Source: OTC Markets, Yahoo Finance, SEC filings)

Corporate News and Market Drivers

RTSL has developed three (3) proprietary pharmaceutical formulas, two (2) for cannabidiol (CBD) and one (1) for cannabigerol (CBG), to initially be used in Metered Dose Inhalers (MDI).

One CBD formula is expected to be used in testing of the MDI which the Company plans to submit to the U.S. Food and Drug Administration (FDA) in connection with an Investigational New Drug Application (IND), as previously announced. The other two are planned to be used in RTSL’s other products.

Rapid Therapeutic Science Laboratories Secures Upgraded Laboratory and Manufacturing Facility

 DALLAS, Nov. 11, 2021 (GLOBE NEWSWIRE) – RTSL announces launch of its new facility located in Addison, Tex.

 The new 8,566 square foot property, for which the Company has secured a five-year lease, is more than double the size of the Company’s current facility and provides four times the storage of raw material and outside storage.

The facility will house a filling lab to be built to ISO 13485 Standard with 350% more capacity for MDI than the Company’s current facility, sublingual and topical aerosol, an isolate manufacturing lab with the capacity to make 15 kilos per day of pharmaceutical grade isolate and corporate offices to hold 20 staff.

Click on above link to read the rest of the story.

Rapid Therapeutic Science Laboratories Adds Two Independent Directors to Company’s Board

Company Fulfills Important Nasdaq Requirements with Appointment of Dr. Henry Punzi and Justin Suggs as Independent Board Members

DALLAS, Nov. 02, 2021 (GLOBE NEWSWIRE) – RTSL today announces the appointment of two independent directors to its Board of Directors. Dr. Henry Punzi and Mr. Justin Suggs join Rapid Therapeutic’s Board.

“The addition of Dr. Punzi and Mr. Suggs is an important step in the evolution of Rapid Therapeutic, as it adds important and diversified expertise to our Board in both the medical and practice management areas.

It also fulfills the important Nasdaq requirement of appointing independent Board members in order for us to up-list onto that major exchange,” commented Donal Schmidt, Rapid Therapeutic’s CEO. “We welcome both gentlemen to our Company and look forward to the benefit of their guidance.”

Click on above link to read the rest of the story.

  Key Corporate Highlights:

• Clean balance sheet – 10-Q of 09/30/2021 shows $900,000+ in cash and the Company states that it has less than $200,000 in Long Term Debt
• Management team has 75+ years of successful private/public company experience in the hemp domain and capital markets
• Manufactures patent-pending pharmaceutical-grade isolates in its own lab
• Proprietary filling process using super-pure patent-pending formulas with 98% bioavailability – well positioned to replace vape pens, edibles & tinctures
• Plans to go to market with its sublingual products in the 4th Qtr. 2021, or shortly thereafter. Sublingual products branded under the name “Yoka”

 To view and download the Company’s most recent corporate presentation CLICK HERE

Interested investors can find out more about Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) on the Company’s website at www.rtslco.com, or by contacting:

Donal (Don) R. Schmidt, Jr.
Chairman and CEO
[email protected]

Phone: 800-497-6059

______________________________________________________________________

Bottom Line Observation

RTSL seems to be well positioned for an upward movement… it is trading closer to its 52-week low of $0.14 than to its 52-week high of $0.80…and has multiple catalysts that could drive the share price higher… including:

•  S-1 offering for $10,000,000+ being declared effective by the SEC
•  Successful up-listing to NASDAQ as stated in recent 10-Q
•  Rapid ramp-up of revenues for “Yoka Sublingual Spray”

 Interested investors might want to keep RTSL on their radar screens or even start building a position in the shares.

______________________________________________________________________

 Disclaimer and Disclosures: MicroCap MarketPlace (MCMP) is a financial publisher and not a FINRA broker/dealer or investment adviser. MCMP is not registered with the SEC / U.S. Securities and Exchange Commission or any state securities regulatory agency. Readers, subscribers and web site visitors are responsible for individual investment decisions. All information contained in our newsletters or on our web site and in our blogs should be independently verified with the featured companies and readers should always conduct their own research and due diligence and engage professional investment advisers as they deem appropriate before making investment decisions. Please review the Terms and Conditions of Use, including without limitation all disclaimers of warranties and limitations on liability contained therein. Your use of any information on our websites, contained herein or in our newsletters and blogs constitutes your agreement of same. MCMP did not receive any compensation for this article. However, officers, employees and affiliates may hold positions in the featured securities discussed in our newsletters or on our web site and blogs and may buy or sell said securities at any time without further notice. MCMP and/or affiliates may from time to time receive cash and/or equity compensation from featured companies for corporate communications services. In the interest of full disclosure, Mike Casson, MCMP’s Executive Editor and president of Casson Communications, LLC (CCLLC), an affiliated company received twenty-seven thousand two hundred fifty dollars in cash compensation and fifty-thousand shares of restricted common stock from the subject company in 2020 for corporate communication services. You should be aware of these potential conflicts of interest. We believe the information contained herein and in our publications to be reliable but cannot guarantee its accuracy; therefore, all information is provided as is without warranty of any kind. Past results are not necessarily indicative of future performance.

 SOURCE

Research and Editorial Staff

MicroCapMarketPlace.com

© 2022 MicroCapMarketPlace, All Rights Reserved

 

Posted by AIA Research & Editorial Staff
Categories: Uncategorized